Prostate Cancer Test Not Worth Risk, Advisory Panel Says

Law360, New York (May 22, 2012, 3:44 PM EDT) -- A government-backed panel of independent medical experts on Monday recommended against use of a controversial test for prostate cancer, drawing scorn from industry organizations and potentially rekindling a smoldering debate over the risks of overtreatment.

The U.S. Preventive Services Task Force, which consists largely of primary care physicians and specialists, gave the prostate-specific antigen test its lowest grade of D, which applies when the group has "moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits."

"There is...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.